Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Jochems A, van der Kooij MK, Fiocco M, Schouwenburg MG, Aarts MJ, van Akkooi AC, van den Berkmortel FWPJ, Blank CU, van den Eertwegh AJM, Franken MG, de Groot JB, Haanen JBAG, Hospers GAP, Koornstra RH, Kruit WHJ, Louwman M, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl MCT, van der Hoeven KJM, Kapiteijn E.

Cancers (Basel). 2019 Jul 18;11(7). pii: E1007. doi: 10.3390/cancers11071007.

2.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM.

Lancet Oncol. 2018 Jul;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. Epub 2018 Jun 13.

PMID:
29908991
3.

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.

Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, van Akkooi ACJ, van den Berkmortel FWPJ, Blokx WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM.

Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453.

PMID:
29750749
4.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM.

Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629.

PMID:
29659371
5.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA.

Anticancer Drugs. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628.

PMID:
29634490
6.

Pimasertib-associated ophthalmological adverse events.

van Dijk EHC, Kruit WHJ, Jager MJ, Luyten GPM, Vingerling JR, Boon CJF.

Acta Ophthalmol. 2018 Nov;96(7):712-718. doi: 10.1111/aos.13677. Epub 2018 Jan 16.

7.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ.

Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25.

PMID:
28030784
8.

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment.

Kloth JSL, Hamberg P, Mendelaar PAJ, Dulfer RR, van der Holt B, Eechoute K, Wiemer EAC, Kruit WHJ, Sleijfer S, Mathijssen RHJ.

Eur J Cancer. 2016 Mar;56:101-106. doi: 10.1016/j.ejca.2015.12.019. Epub 2016 Feb 1.

PMID:
26841094
9.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group.

Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17.

PMID:
26790144
10.

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.

Kloth JS, Pagani A, Verboom MC, Malovini A, Napolitano C, Kruit WH, Sleijfer S, Steeghs N, Zambelli A, Mathijssen RH.

Br J Cancer. 2015 Mar 17;112(6):1011-6. doi: 10.1038/bjc.2015.82.

11.

The Importance of Long-Term Surveillance of Stage IB Melanomas: Unexpectedly Low Survival Subsequent to Recurrence.

Leeneman B, Franken MG, Blommestein HM, van Gils CW, van der Meijde E, Wouters MW, Plaisier PW, Kruit WH, van Ruth S, Ten Tije AJ, Hendriks MP, Coupe VM, Uyl-de Groot CA.

Value Health. 2014 Nov;17(7):A618-9. doi: 10.1016/j.jval.2014.08.2187. Epub 2014 Oct 26. No abstract available.

12.

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A.

J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9.

PMID:
24019551
13.

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U.

J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.

PMID:
23715572
14.

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG.

J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.

PMID:
23715562
15.

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).

Busse A, Rapion J, Fusi A, Suciu S, Nonnenmacher A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U.

Cancer Immunol Immunother. 2013 Jul;62(7):1223-33. doi: 10.1007/s00262-013-1428-4. Epub 2013 Apr 27.

PMID:
23624802
16.

[Revision of the national guideline 'Melanoma'].

Veerbeek L, Kruit WH, de Wilt J, Mooi WJ, Bergman W; Multidisciplinaire Richtlijnwerkgroep Melanoom.

Ned Tijdschr Geneeskd. 2013;157(12):A6136. Dutch.

PMID:
23515047
17.

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U.

J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24.

PMID:
23008300
18.

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A.

Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5.

PMID:
22056637
19.

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A; EORTC Melanoma Group.

Eur J Cancer. 2011 Jul;47(10):1476-83. doi: 10.1016/j.ejca.2011.04.030. Epub 2011 May 18.

PMID:
21600759
20.

Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome.

Bouwhuis MG, Collette S, Suciu S, de Groot ER, Kruit WH, Ten Hagen TL, Aarden LA, Eggermont AM, Swaak AJ; EORTC Melanoma Group.

Melanoma Res. 2011 Aug;21(4):344-51. doi: 10.1097/CMR.0b013e328346c17f.

PMID:
21546857
21.

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

Bouwhuis MG, Suciu S, Testori A, Kruit WH, Salès F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM.

J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12.

PMID:
20385998
22.

[Improved compliance with the 'Melanoma' treatment guideline].

Veerbeek L, van de Poll-Franse LV, Bekkenk MW, Bergman W, Hoekstra HJ, Jansen-Landheer ML, Kruit WH, Mooi WJ, de Vries E, van der Rhee HJ.

Ned Tijdschr Geneeskd. 2010;154:A858. Dutch.

PMID:
20170570
23.

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).

Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U.

Eur J Cancer. 2009 Dec;45(18):3189-97. doi: 10.1016/j.ejca.2009.09.004. Epub 2009 Sep 28.

PMID:
19793643
24.

Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).

Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C.

Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7. doi: 10.1007/s00280-009-1072-z. Epub 2009 Jul 21.

PMID:
19621225
25.

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group.

J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. doi: 10.1093/jnci/djp132. Epub 2009 Jun 9.

PMID:
19509353
26.

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.

Fekkes D, Van Gool AR, Bannink M, Sleijfer S, Kruit WH, van der Holt B, Eggermont AM, Hengeveld MW, Stoter G.

Amino Acids. 2009 Oct;37(4):703-8. doi: 10.1007/s00726-008-0191-x. Epub 2008 Oct 26.

27.

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.

Van Gool AR, Verkerk R, Fekkes D, Bannink M, Sleijfer S, Kruit WH, van der Holt B, Scharpé S, Eggermont AM, Stoter G, Hengeveld MW.

Psychiatry Clin Neurosci. 2008 Oct;62(5):597-602. doi: 10.1111/j.1440-1819.2008.01854.x.

28.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group.

Lancet. 2008 Jul 12;372(9633):117-26. doi: 10.1016/S0140-6736(08)61033-8.

29.

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma.

Van Gool AR, Verkerk R, Fekkes D, Sleijfer S, Bannink M, Kruit WH, van der Holt B, Scharpé S, Eggermont AM, Stoter G, Hengeveld MW.

J Interferon Cytokine Res. 2008 May;28(5):283-6. doi: 10.1089/jir.2007.0058.

PMID:
18547158
30.

[Viewpoint of the Dutch Melanoma Working Group regarding sentinel lymph node biopsy: prognostic but not therapeutic implications].

Kruit WH; Dutch Melanoma Working Group.

Ned Tijdschr Geneeskd. 2008 Mar 8;152(10):574-6. Dutch.

PMID:
18402325
31.

[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF.

Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Review. Dutch.

PMID:
18380383
32.

Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.

Bannink M, Kruit WH, Van Gool AR, Sleijfer S, van der Holt B, Eggermont AM, Stoter G, Hengeveld MW.

Psychosomatics. 2008 Jan-Feb;49(1):56-63. doi: 10.1176/appi.psy.49.1.56.

PMID:
18212177
33.

Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.

Bannink M, Fekkes D, Van Gool AR, Kruit WH, Sleijfer S, van der Holt B, Eggermont AM, Stoter G, Hengeveld MW.

Neuropsychobiology. 2007;55(3-4):225-31. Epub 2007 Sep 17.

PMID:
17873497
35.

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E.

J Clin Oncol. 2006 May 1;24(13):e20-2. No abstract available.

PMID:
16648493
36.

Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients.

Fekkes D, Bannink M, Kruit WH, Van Gool AR, Mulder PG, Sleijfer S, Eggermont AM, Stoter G.

Amino Acids. 2007 Jan;32(1):121-6. Epub 2006 Apr 20.

PMID:
16622596
37.

Side effects of interferon-alpha therapy.

Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G.

Pharm World Sci. 2005 Dec;27(6):423-31.

PMID:
16341948
38.

[Guideline 'Melanoma' (3rd revision)].

van Everdingen JJ, van der Rhee HJ, Koning CC, Nieweg OE, Kruit WH, Coebergh JW, Ruiter DJ; Nederlandse Melanoom Werkgroep.

Ned Tijdschr Geneeskd. 2005 Aug 13;149(33):1839-43. Dutch.

PMID:
16128181
39.

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M.

Int J Cancer. 2005 Nov 20;117(4):596-604.

40.

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.

Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, Gratama JW, Stoter G, Huber C, Hack CE.

Cancer Immunol Immunother. 2005 Jan;54(1):37-43.

PMID:
15693137
41.

Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients.

Bannink M, Kruit WH, Van Gool AR, Mulder PG, Sleijfer S, Eggermont AM, Stoter G, Fekkes D.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):109-14. Epub 2004 Nov 18.

PMID:
15610952
42.

Thalidomide in solid tumours: the resurrection of an old drug.

Sleijfer S, Kruit WH, Stoter G.

Eur J Cancer. 2004 Nov;40(16):2377-82. Review.

PMID:
15519508
43.

Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.

Lamers CH, Sleijfer S, Willemsen RA, Debets R, Kruit WH, Gratama JW, Stoter G.

J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):134-40. Review.

PMID:
15471217
45.

Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.

Van Gool AR, Van Ojik HH, Kruit WH, Mulder PG, Fekkes D, Bannink M, Scharpé S, Stoter G, Eggermont AM, Maes M, Verkerk R.

J Interferon Cytokine Res. 2004 Jul;24(7):411-5.

PMID:
15296652
46.

Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations.

Van Gool AR, van Ojik HH, Kruit WH, Bannink M, Mulder PG, Eggermont AM, Stoter G, Fekkes D.

Anticancer Drugs. 2004 Jul;15(6):587-91.

PMID:
15205601
47.

Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients.

Van Gool AR, Fekkes D, Kruit WH, Mulder PG, Ten Hagen TL, Bannink M, Maes M, Eggermont AM.

Psychiatry Res. 2003 Jul 15;119(1-2):125-32.

PMID:
12860366
48.

Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.

Kivelä T, Suciu S, Hansson J, Kruit WH, Vuoristo MS, Kloke O, Gore M, Hahka-Kemppinen M, Parvinen LM, Kumpulainen E, Humblet Y, Pyrhönen S.

Eur J Cancer. 2003 May;39(8):1115-20.

PMID:
12736111
49.

Neuropsychiatric side effects of interferon-alfa therapy.

Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM.

Pharm World Sci. 2003 Feb;25(1):11-20. Review.

PMID:
12661471
50.

IL-12: a promising adjuvant for cancer vaccination.

Portielje JE, Gratama JW, van Ojik HH, Stoter G, Kruit WH.

Cancer Immunol Immunother. 2003 Mar;52(3):133-44. Epub 2003 Feb 12. Review.

PMID:
12649742

Supplemental Content

Loading ...
Support Center